Business Models in a New Digital Culture: The Open Long Tail Model

New business models are emerging in global markets. Quirky is producing new products designed and developed by the community and finally produced by the 3D printing technology. Google gives his glasses to different developers who build up their own applications. Kickstarter finds the funders by the use of the crowd, paying them back with the future products. Employees, funders, customers and partners do not play a stable role with the organization but revolve around it using different form of collaborations related to the organization’s needs. In this scenario business like Amazon find out their own achievement feeding up different customers’ needs

DANGO (Doings and Goings On) - Vol. 22 | Issue 11

ACU Department of Engineering and Physics Summer Research Newsletterhttps://digitalcommons.acu.edu/dango/1010/thumbnail.jp

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Towards Horizon 2020:challenges and advances for clinical mental health research - outcome of an expert survey

Background: The size and increasing burden of disease due to mental disorders in Europe poses substantial challenges to its population and to the health policy of the European Union. This warrants a specific research agenda concerning clinical mental health research as one of the cornerstones of sustainable mental health research and health policy in Europe. The aim of this research was to identify the top priorities needed to address the main challenges in clinical research for mental disorders. Methods: The research was conducted as an expert survey and expert panel discussion during a scientific workshop. Results: Eighty-nine experts in clinical research and representing most European countries participated in this survey. Identified top priorities were the need for new intervention studies, understanding the diagnostic and therapeutic implications of mechanisms of disease, and research in the field of somatic-psychiatric comorbidity. The “subjectivity gap” between basic neuroscience research and clinical reality for patients with mental disorders is considered the main challenge in psychiatric research, suggesting that a shift in research paradigms is required. Conclusion: Innovations in clinical mental health research should bridge the gap between mechanisms underlying novel therapeutic interventions and the patient experience of mental disorder and, if present, somatic comorbidity. Clinical mental health research is relatively underfunded and should receive specific attention in Horizon 2020 funding programs

Conceptual Framework for a New Tool for Evaluating the Quality of Diabetes Consumer-Information Web Sites

BACKGROUND: Most existing tools for measuring the quality of Internet health information focus almost exclusively on structural criteria or other proxies for quality of information, rather than evaluating information accuracy and comprehensiveness. OBJECTIVE: This research sought to build a conceptual framework that could lay the groundwork for a robust performance-measurement system for evaluating the quality of Internet health information. METHODS: Application of the quality-of-care measurement paradigm to developing a conceptual framework for defining and evaluating the quality of diabetes consumer-information Web sites. RESULTS: Performance measures related to accuracy and comprehensiveness of information can be added to structural criteria to provide a more-robust approach to Web site evaluation. CONCLUSIONS: The development and implementation of a reliable and valid method for evaluating the quality of Internet health sites could provide lay people with a tool to identify useful content more easily and distinguish between beneficial and misleading information

Atmospheric sulfur cycle simulated in the global model GOCART: Comparison with field observations and regional budgets

We present a detailed evaluation of the atmospheric sulfur cycle simulated in the Georgia Tech/Goddard Global Ozone Chemistry Aerosol Radiation and Transport (GOCART) model. The model simulations of SO2, sulfate, dimethylsulfide (DMS), and methanesulfonic acid (MSA) are compared with observations from different regions on various timescales. The model agrees within 30% with the regionally averaged sulfate concentrations measured over North America and Europe but overestimates the SO2 concentrations by more than a factor of 2 there. This suggests that either the emission rates are too high, or an additional loss of SO2 which does not lead to a significant sulfate production is needed. The average wintertime sulfate concentrations over Europe in the model are nearly a factor of 2 lower than measured values, a discrepancy which may be attributed largely to the sea-salt sulfate collected in the data. The model reproduces the sulfur distributions observed over the oceans in both long-term surface measurements and short-term aircraft campaigns. Regional budget analyses show that sulfate production from SO2 oxidation is 2 to 3 times more efficient and the lifetimes of SO2 and sulfate are nearly a factor of 2 longer over the ocean than over the land. This is due to a larger free tropospheric fraction of SO2 column over the ocean than over the land, hence less loss to the surface. The North Atlantic and northwestern Pacific regions are heavily influenced by anthropogenic activities, with more than 60% of the total SO2 originating from anthropogenic sources. The average production efficiency of SO2 from DMS oxidation is estimated at 0.87 to 0.91 in most oceanic regions